Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts

Last Updated: January 25, 2020

DrugPatentWatch Database Preview

Patent: 7,202,361

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Summary for Patent: 7,202,361
Title:Antitumoral ecteinascidin derivatives
Abstract: This invention relates to compounds of the formula: ##STR00001## wherein: the substituent groups defined by R.sub.1, R.sub.2 are each independently selected of H, C(.dbd.O)R\', C.sub.1 C.sub.18 alkyl, C.sub.2 C.sub.18 alkenyl, C.sub.2 C.sub.18 alkynyl, or aryl; each of the R\' groups is independently selected from the group consisting of H; OH; NO.sub.2; NH.sub.2; SH; CN; halogen; .dbd.O; C(.dbd.O)H; C(.dbd.O)CH.sub.3; CO.sub.2H; or C.sub.1 C.sub.18 alkyl, C.sub.2 C.sub.18 alkenyl, C.sub.2 C.sub.18 alkynyl, or aryl, each of which, independently, may be substituted with one or more substituents selected from the group consisting of halogen, cyano, hydroxy, nitro, azido; alkanoyl, carboxamido, alkyl, alkenyl, alkynyl, aryloxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, aminoalkyl, carbocylic aryl having 6 or more carbons, and aralkyl; X.sub.2 is OX.sub.1 or N(X.sub.1).sub.2 wherein each X.sub.1 is independently H, C(.dbd.O)R\' where R\' is as defined, C.sub.1 C.sub.18 alkyl, C.sub.2 C.sub.18 alkenyl, C.sub.2 C.sub.18 alkynyl, aryl, alkoxy, heterocyclyl, or two X.sub.1 groups together form a cyclic substituent on the nitrogen atom, or X.sub.1 is SO.sub.2CH.sub.3 when X.sub.2 is OX.sub.1, or N(X.sub.1).sub.2 is NHCOalkylCOOH, Nilbiotin, NH(aa).sub.y where aa is amino acid acyl andy is 1, 2 or 3 optionally with a amide terminal group, protected NHCOCH(NH.sub.2)CH.sub.2SH, NHCOalkenylaryl substituted with CF.sub.3, or m-methoxycarbonylbenzoylNH; wherein N(X.sub.1).sub.2 is not NH.sub.2; X.sub.3 is selected of OR.sub.1 where R.sub.1 is as defined, CN, (.dbd.O), or H; X.sub.4 is--H or C.sub.1 C.sub.18 alkyl; and X.sub.5 is selected of H, or R.sub.1 where R.sub.1 is as defined; provided that the compound is not ecteinascidin 583 or 597, which are useful for treating tumors.
Inventor(s): Flores; Maria (Seville, ES), Francesch; Andres (Madrid, ES), Gallego; Pilar (Madrid, ES), Chicharro; Jose Luis (Madrid, ES), Zarzuelo; Maria (Madrid, ES), Fernandez; Carolina (Madrid, ES), Manzanares; Ignacio (Madrid, ES)
Assignee: PharmaMar (Madrid, ES)
Application Number:10/240,963
Patent Claims:see list of patent claims

Details for Patent 7,202,361

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Start Trial PharmaMar (Madrid, ES) 2020-04-12 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.